Here, we report a rare case of primary mediastinal malignant meningioma with lung and bone metastases, who benefited from the treatment of apatinib (≥33 months) and anlotinib (until the publication date). Based on the Western analysis, we revealed that FGF6 can promote the phosphorylation of FGFR, AKT, and ERK1/2, which can be inhibited by anlotinib. Together, we were the first to verify that overexpression of FGF6 promotes the progression of malignant meningiomas by activating FGFR/AKT/ERK1/2 pathway and pointed out that anlotinib may effectively inhibit the disease progression of patients with FGF6 amplification.

P1/2, N=15, Active, not recruiting, AsclepiX Therapeutics, Inc. | Recruiting --> Active, not recruiting

P1, N=29, Terminated, Elevar Therapeutics | Phase classification: P1b/2 --> P1 | Completed --> Terminated; Phase 2 portion of the study was not performed due to redirection of the rivoceranib development plan by the Sponsor.

P2, N=21, Completed, Washington University School of Medicine | Active, not recruiting --> Completed

P2, N=196, Active, not recruiting, RenJi Hospital | Completed --> Active, not recruiting | Trial completion date: Apr 2023 --> Mar 2031

These findings highlight the substantial anticancer potential of tivozanib in OSCC and thus its promise as a therapeutic option. Beyond reducing cell viability and inducing apoptosis, the capacity of tivozanib to inhibit EMT and modulate key proteins presents the possibility of a paradigm shift in OSCC treatment.

Ramucirumab may be equally useful in patients with unresectable HCC who have poor liver function or whose liver function is aggravated by other therapies. Rechallenge treatment with lenvatinib after ramucirumab may be a valid treatment option for HCC.

Ethics approval has been obtained from the Ethics Committee at the First Affiliated Hospital (Xijing Hospital) of Air force Military Medical University (KY20232220-F-1). This trial has been registered at the ClinicalTrials.gov: NCT06169410 (registration date: December 5, 2023).

Low-dose apatinib combined with oral vinorelbine demonstrates potential efficacy and well tolerated for pretreated HER2-negative mBC.

P1/2, N=198, Recruiting, Akeso | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Feb 2023 --> Dec 2024

P2, N=40, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting

P2, N=168, Recruiting, Canadian Cancer Trials Group | Not yet recruiting --> Recruiting

P=N/A, N=234, Completed, Fujian Medical University

Data provide new insights into the molecular mechanisms involved in CDPs cytotoxicity and antiproliferative effects, suggesting that the signal transduction mechanism may be related to the inhibition of the phosphorylation of the EGF/MET receptor at the level of substrate binding site by an inhibition mechanism similar to that of Gefitinib and foretinib anti-neoplastic drugs.

P2, N=57, Recruiting, Fujian Medical University | Not yet recruiting --> Recruiting

P1, N=30, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Phase classification: P2 --> P1 | Initiation date: Jun 2023 --> Jun 2024

On the contrary, some patients with mucosal, acral or KIT-mutant melanoma may benefit from TKI-based therapies. Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma.

P2, N=57, Not yet recruiting, Fujian Medical University

P2/3, N=224, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Mar 2024 --> Jun 2024

P2, N=23, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Mar 2024 --> Jul 2024

P1/2, N=47, Terminated, Basilea Pharmaceutica | Phase classification: P1b/2 --> P1/2

P3, N=506, Not yet recruiting, Akeso

P2, N=30, Not yet recruiting, Chinese PLA General Hospital

P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

There was no obvious difference in body weight and liver and kidney functions between the four groups of mice. In conclusion, CPT improves the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.

In summary, ramucirumab may have similar effectiveness as bevacizumab in combination with an EGFR-TKI as first line therapy for advanced lung adenocarcinoma harboring susceptible EGFR mutation. Further large-scale registry-based cohort studies may be needed to validate our findings.

P1/2, N=6, Terminated, AsclepiX Therapeutics, Inc. | Completed --> Terminated; Adverse Events

P1/2, N=3, Terminated, AsclepiX Therapeutics, Inc. | Completed --> Terminated; Adverse Events

P1, N=50, Recruiting, Etnova Therapeutics Corp.

P3, N=545, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2023 --> Dec 2024

Mechanistically, CPD-002 hindered the activation of VEGFR2/PI3K/AKT pathway in VEGF-induced HUVECs and AIA rat synovium, as evidenced by reduced p-VEGFR2, p-PI3K, and p-AKT protein levels alongside elevated PTEN protein levels. Totally, CPD-002 showed anti-rheumatoid effects via attenuating angiogenesis through the inhibition of the VEGFR2/PI3K/AKT pathway.

In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/- ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/- ramucirumab in this patient population.

Progression-free survival in the CA125-increased group, defined by an increase of 0.0067%/day using receiver operating characteristic curve analysis, was significantly poorer among patients with peritoneal metastases. In conclusion, this study highlights that CA125 kinetics can serve as an early predictor for the progression of peritoneal metastasis during TAX/RAM treatment.

P2, N=16, Not yet recruiting, M.D. Anderson Cancer Center

Herein, we report the discovery of a novel structure of potent chalcone-based derivatives type II c-Met inhibitors which are comparable to Foretinib (IC50 = 14 nM) as a potent reference drug...However, the weak inhibitory effects on microtubules were confirmed by cell cycle analyses implicated that the observed cytotoxicity against HeLa cells probably was not derived from tubulin inhibition. Compounds 14q and 14k with IC50 values of 24 nM and 45 nM, respectively, demonstrated favorable inhibition of MET kinase activity, and desirable bonding interactions in the ligand-MET enzyme complex stability in molecular docking studies.

P2, N=196, Completed, RenJi Hospital | Recruiting --> Completed | Trial primary completion date: Oct 2022 --> Mar 2023

P3, N=490, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

Medical records of patients with aGEC enrolled in the randomized phase II AIO-STO-0417 trial after treatment failure to first-line FOLFOX plus nivolumab and ipilimumab were retrospectively analyzed...Patients with CPS ≥1 in the RAM group showed better tumor control (ORR 25% vs 10%) and improved survival (total OS 11.5 vs 8.0 months; second-line OS 6.5 vs 3.9 months; PFS 4.5 vs 1.6 months) compared to the control. Prior exposure to first-line FOLFOX plus dual checkpoint inhibition followed by RAM plus chemotherapy shows favorable response and survival rates especially in patients with initial response and positive PD-L1 expression and has the potential to advance the treatment paradigm in aGEC.

Apatinib has a significant inhibitory effect on small cell lung cancer with high expression of VEGFR2 and may be a treatment for small cell lung cancer patients.

P1, N=35, Recruiting, First Affiliated Hospital of Fujian Medical University | Not yet recruiting --> Recruiting

P2, N=170, Recruiting, Sun Yat-sen University

P2, N=48, Recruiting, Asan Medical Center | Not yet recruiting --> Recruiting